Skip Ribbon Commands
Skip to main content

Find a Doctor

A/Prof Edmund Chiong

Photo of A/Prof Edmund Chiong
Designations:
  • Head & Senior Consultant, Department of Urology, National University Hospital
  • Senior Consultant, Division of Surgical Oncology, National University Cancer Institute, Singapore
  • Associate Professor, Department of Surgery, Yong Loo Lin School of Medicine, NUS
  • Cluster Sub-Specialty Lead for Urology, National University Health System, Singapore
  • Co-Chair, NUHS Robotic Surgery Program Steering Committee (NRSPSC), National University Health System, Singapore
  • Member, Associate Professorial Faculty Promotion and Tenure Committee (APFPTC), Yong Loo Lin School of Medicine, National University Singapore
  • Past President (2016-2018) & Board of Trustees Member, Singapore Urological Association
  • Vice Chairman, Chapter of Urologists (College of Surgeons), Academy of Medicine, Singapore
  • Chairman, Examinations Committee for Urology, Residency Advisory Committee (Urology) & Joint Committee on Specialist Training (JCST), Singapore
  • Deputy Chairman, Scientific Committee, Urological Association of Asia (UAA)
Qualifications:
MBBS (Singapore), Ph.D, FRCSEd, FRCSI, FAMS (Urology)
Specialties:
Cancer, Surgery
Sub-specialties:
Surgical Oncology (Urology), Urology
Special Interests:
Uro-oncology (Prostate cancer, Kidney cancer, Bladder cancer, Testicular cancer and Penile cancer) , Prostate cancer High-Dose Rate Brachytherapy , Da Vinci Robotic surgery , General Urology
Investigating diagnostic modalities and new therapies for Bladder cancer (including immunotherapy, gene therapy and targeted therapy), Prostate cancer and other Urologic malignancies. Minor interest in urinary tract infections and medical device innovation

Biosketch

A/Prof Edmund Chiong graduated with the degrees of Bachelor of Medicine and Surgery from the National University of Singapore (NUS) in 1995. He obtained postgraduate qualifications (Fellow of the Royal College of Surgeons of Edinburgh and Fellow of the Royal College of Surgeons In Ireland) in Surgery and completed of his Urology specialist training in Singapore. A/Prof Chiong subsequently completed a 2-year clinical fellowship program in Urologic Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.  He is also certified by the Society of Urologic Oncology, USA.

A/Prof Chiong’s subspecialty interests include managing and performing surgery for prostate cancers, bladder cancers, kidney cancers, testes cancers, penile cancers, and performing DaVinci robotic surgery. A/Prof Chiong also manages general urologic diseases and is a kidney transplant surgeon with the Ministry of Health’s renal transplantation team. Apart from clinical practice, A/Prof Chiong is also actively involved in both clinical and laboratory research. His research interests include diagnostic modalities and new therapies for Bladder cancer (including immunotherapy, gene therapy and targeted therapy), Prostate cancer and other Urologic malignancies. He has minor interests in investigating urinary tract infections, and medical device innovation.

He is an investigator in a number of grant-funded, clinical and basic science research projects. He was conferred a PhD (NUS) for his thesis on targeted therapy for bladder cancer. He also runs a number of clinical trials in bladder and prostate cancer. A/Prof Chiong has received more than 35 academic and fellowship awards, authored or co-authored a number of papers in peer-reviewed journals, and have presented more than 350 lectures and abstracts at regional or international scientific meetings. He is also a reviewer for many leading international urology and cancer journals.

A/Prof Chiong is Past President (2016-2018) and current Board of Trustees member of the Singapore Urological Association, is currently Vice Chairman of the Chapter of Urologists (College of Surgeons), Academy of Medicine, Singapore, and Chairman of the Examinations Committee for Urology and Board member, Residency Advisory Committee / Joint Committee on Specialist Training (JCST), Ministry of Health, Singapore. He is also the Deputy Chairman, Scientific Committee, Urological Association of Asia (UAA), a member of the American Urological Association, European Association of Urology and the American Society of Clinical Oncology. 


Awards

Research / Best Paper Awards (selected)

  1. NUH Young Doctor (Merit) Award at 7th National University of Singapore – National University Hospital Annual Scientific Meeting (Singapore, 2003)

  2. Best Poster Presentation Award [Surgery / Obstetrics & Gynaecology / Dentistry / Ophthalmology (Clinical) category] at National Healthcare Group Annual Scientific Congress 2004 (Singapore, 2004)

  3. Best Clinical Podium Presentation Award / The Singapore Urological Association Bookprize at Urology Fair 2005 (The Singapore Urological Association Annual Scientific Meeting) (Singapore, 2005).

  4. Best Basic Science Oral Presentation Award at Urology Fair 2005 (The Singapore Urological Association Annual Scientific Meeting), (Singapore, 2005).

  5. NHG Doctor Award at Combined Scientific Meeting 2005 (Singapore, 2005)

  6. Best NHG Oral Presentation Award [Surgical disciplines category] at Combined Scientific Meeting 2005 (Singapore, 2005)

  7. Best Oral Podium Presentation Award / The Singapore Urological Association Bookprize at Urology Fair 2006 (The Singapore Urological Association Annual Scientific Meeting), (Singapore, 2006)

  8. Best Oral Presentation Award / Department of Surgery research prize at Pitch for Funds Round, Clinician Scientist Unit, NUS Leadership In Academic Medicine Program, National University of Singapore (Singapore, 2006)

  9. ASCO Cancer Foundation Merit Award at American Society of Clinical Oncology (ASCO) 2009 Genitourinary Cancers Symposium (Orlando, Florida, USA, 2009).

  10. Best Poster Presentation Award (Surgical Disciplines category) at National Healthcare Group 8th Annual Scientific Congress (Singapore, 2009).

  11. Young Investigator Merit Award (Basic Science / Translational Research category) at National Healthcare Group 8th Annual Scientific Congress (Singapore, 2009).

  12. Best Poster Presentation Award at 25th Anniversary European Association of Urology Congress (EAU) 2010 (Barcelona, Spain, 2010).

  13. Best Poster Presentation Award at 10th Asian Congress of Urology of the Urological Association of Asia (Taipei, Taiwan, 2010).

  14. Best Video Presentation Award at Urofair 2012 (The Singapore Urological Association Annual Scientific Meeting), (Singapore, 29 to 31 March 2012).

  15. 17th Yahya Cohen Memorial Lectureship Award 2012, (Competitive) College of Surgeons, Academy of Medicine, Singapore (Singapore, 3 August, 2012).

  16. Best Oral Presentation Award at 2nd National Kidney Foundation (NKF) Scientific Meeting 2014 (Singapore, 22 March 2014).

  17. MOE Innergy Award (Silver) – group from NUS, NUHS and ITE (Percutaneous access to Kidney assist device (PAKAD) for Kidney Stone surgery project) (Singapore, November 2015).

  18. Best Surgical Oncology Poster Award, 3rd NCIS Annual Research Meeting (NCAM), NCIS, NUHS (Singapore, 1 July 2016).

  19. Outstanding Paper Award 2019, Asian Journal of Andrology.

Reviewer Awards

  1. Reviewer Recognition Award 2012, Singapore Medical Journal (Singapore, 19 February 2013).

  2. Reviewer Recognition Award 2013, Singapore Medical Journal (Singapore, 15 January 2014).

  3. Annals Gold Reviewer Award 2013, Annals Academy of Medicine, Singapore (Singapore, 25 October 2014).

  4. Outstanding Contribution in Reviewing award, Urologic Oncology: Seminars & Original Investigations journal (Feb 2017)

  5. Reviewer Recognition certificate, Urologic Oncology: Seminars & Original Investigations journal (May 2018)

Journals & Publications

Selected Published Papers
  1. Wang Z, Ong WYF, Tong S, Sng JH, Lata RM, Mahendran R, Kesavan E, Chiong E. Beyond diabetes mellitus: role of metformin in non-muscle invasive bladder cancer. SMJ 2020 Aug 17.  doi: 10.11622/smedj.2020121. 
  2. Lee SH, Mahendran R, Tham SM, Thamboo TP, Chionh BJ, Lim YX, Tsang WC, Wu QH, Chia JY, Tay MHW, Goh BYS, Chen KW, Mallari JZ, Periaswami R, Raman L, Choo SN, Kioh DYQ, Chiong E, Esuvaranathan K, Chan ECY. Tryptophan-kynurenine ratio as a biomarker of bladder cancer. BJUI 2020 Aug 13. doi: 10.1111/bju.15205. 
  3. Lee SH, Mahendran R, Tham SM, Thamboo TP, Kioh DYQ, Tang LWT, Chiong E, Esuvaranathan K, Chan ECY. Combination Bacillus Calmette-Guérin and indoleamine 2,3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer. BJUI 2020 Aug 8. doi: 10.1111/bju.15201.
  4. Cheong EJY, Nair PC, Neo RWY, Tu HT, Lin F, Chiong E, Esuvaranathan K, Fan H, Szmulewitz R, Peer CJ, Figg WD, Chai CLL, Miners JO, Chan ECY. Slow tight binding inhibition of CYP17A1 by abiraterone redefines its kinetic selectivity and dosing regimen. J Pharmacol Exp Ther. 2020 Jun 17:jpet.120.265868. doi: 10.1124/jpet.120.265868.
  5. Tan YQ, Wang ZT, Tiong HY, Chua WJ, Wu QH, Chiong E. The START (Surgical Triage And Resource Allocation Tool) of Surgical Prioritisation during the COVID-19 Pandemic. Urology 2020 May 20:S0090-4295(20)30572-0. doi: 10.1016/j.urology.2020.05.021.
  6. Tan YQ, Lu JR, Chiong E. Re: Kristian D. Stensland, Todd M. Morgan, Alireza Moinzadeh, Et Al. Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic. Eur Urol. In Press. https://doi.org/10.1016/j.eururo.2020.03.027: The Forgotten Urological Patient During the COVID-19 Pandemic: Patient Safety Safeguards. Eur Uro 2020 May 8:S0302-2838(20)30340-7. doi: 10.1016/j.eururo.2020.04.072.
  7. Teoh JY, MacLennan S, Chan VW, Miki J, Lee HY, Chiong E, Lee LS, Wei Y, Yuan Y, Yu CP, Chow WK, Poon DM, Chan R, Lai F, Ng CF, Breda A, Kramer MW, Malavaud B, Mostafid H, Herrmann T, Babjuk M. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour incorporating Two Systematic Reviews, a Two-round Delphi Survey and a Consensus Meeting. Eur Urol 2020 Oct;78(4):546-569.
  8. Tham SM, Mahendran R, Chiong E, Wu QH, Esuvaranathan K. Gmcsf and Ifnα gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer. Future Oncol. 2020 Apr 30. doi: 10.2217/fon-2020-0137.
  9. SS Mullapudi, D Mitra, M Li, ET Kang, E Chiong, KG Neoh. Potentiating Anti-cancer Chemotherapeutics and Antimicrobials via Sugar-mediated Strategies. Molecular Systems Design & Engineering 2020 (Mol. Syst. Des. Eng., 2020, 5, 772-791)
  10. Mullapudi SS, Zhang J, Lu S, Rahmat JN, Mahendran R, Kang ET, Chiong E, Neoh KG. Receptor-Targeting Drug and Drug Carrier for Enhanced Killing Efficacy against Non-Muscle-Invasive Bladder Cancer. ACS Applied Bio Materials 2(9):3763-3773 16 Sep 2019.
  11. Khoo BL, Bouquerel C, Durai P, Anil S, Goh B, Wu B, Raman L, Mahendran R, Thamboo T, Chiong E, Lim CT. Detection of Clinical Mesenchymal Cancer Cells from Bladder Wash Urine for Real-Time Detection and Prognosis. Cancers (Basel). 2019 Aug 30;11(9).
  12. Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q. PRL3-zumab as an immunotheraphy to inhibit tumors expressing PRL3 oncoprotein. Nat Commun. 2019 Jun 6;10(1):2484.
  13. Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, Lazzeri M, Guazzoni G, Stephan C, Haese A, Bruijne I, Teoh JY, Leung CH, Casale P, Chiang CH, Tan LG, Chiong E, Huang CY, Wu HC, Nieboer D, Ye DW, Bangma CH, Roobol MJ. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. Eur Urol. 2019 Apr;75(4):558-561.
  14. Mandakhalikar KD, Wang R, Rahmat JN, Chiong E, Neoh KG, Tambyah PA. Restriction of in vivo infection by antifouling coating on urinary catheter with controllable and sustained silver release: A proof of concept study. BMC Infectious Diseases 2018 Aug 6;18(1):370.
  15. Chiong E, Murphy DG, Akaza H, Buchan NC, Chung BH, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Ng CF, Ong T, Pu YS, Saad M, Schubach K, Türkeri L, Umbas R, Vu LC, Williams S, Ye D; ANZUP Cancer Trials Group, Davis ID. Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-word' consideration of results from the Advanced Prostate Cancer Consensus Conference APCCC 2017. BJU Int. 2019 Jan;123(1):22-34.
  16. Wang Z, Lim YK, Lim HCC, Chan YH, Ngiam N, Nee Mani LR, Esuvaranathan K, Ng CF, Teoh J, Chan E, Mahendran R, Chiong E. The Role of Vitamin D Receptor Polymorphisms in Predicting Response to Therapy in Nonmuscle Invasive Bladder Carcinoma. J Urol. 2018 Oct;200(4):737-742.
  17. Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff M, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 May 10;36(14):1389-1395.
  18. Schaefferkoetter JJ, Wang Z, Stephenson MC, Roy S, Conti M, Eriksson L, Townsend DW, Thamboo T, Chiong E. Quantitative 18F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring. EJNMMI Res. 2017 Dec;7(1):55. (Epub)
  19. Li M, Mitra D, Kang ET, Lau T, Chiong E, Neoh KG. Thiol-Ol Chemistry for Grafting of Natural Polymers to Form Highly Stable and Efficacious Antibacterial Coatings. ACS Applied Materials & Interfaces 2017, 9(2):1847-1857
  20. Fernández MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. Clinical Risk Stratification in Patients with Surgically Resectable Micropapillary Bladder Cancer. BJUI 2017 May;119(5):684-691.
  21. Tan LGL, Tan YK, Tai BC, Tan KML, Gauhar V, Tiong HY, Hawkins RCW, Thamboo TP, Hong FSK, Chiong E. Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4–10 ng/ml. Asian Journal of Andrology 2017 May-Jun;19(3):286-290.
  22. Lu S, Xu L, Kang ET, Mahendran R, Chiong E, Neoh KG. Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer. Eur J Pharm Sci. 2016 Jan 15;84:103-115.
  23. Liu Q, Shin Y, Kee JS, Kim KW, Mohamed Rafei SR, Perera AP, Tu X, Lo GQ, Ricci E, Colombel M, Chiong E, Thiery JP, Park MK. Mach-Zehnder interferometer (MZI) point-of-care system for rapid multiplexed detection of microRNAs in human urine specimens. Biosens Bioelectron. 2015 Sep 15;71:365-72.
  24. Kumar P, Nandi S, Tan TZ, Ler SG,  Chia KS,  Lim WY, Bütow Z, Vordos D, laTaille AD, Raida M, Beyer B, Ricci E,  Colombel M, Chong TW, Chiong E, Soo R, Park MK, Ha HK, Gunaratne J, Thiery JP. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. Oncotarget. 2015 May 30;6(15):13539-13549.
  25. Lim HY, Yip YM, Chiong E, Tiong HY, Halliwell B, Esuvaranathan K, Wong KP. Metabolic signatures of Renal Cell Carcinoma. Biochem Biophys Res Commun. 2015 May 15;460(4):938-43.
  26. Lu SJ, Neoh KG, Kang ET, Mahendran R, Chiong E. Mucoadhesive Polyacrylamide Nanogel as a Potential Hydrophobic Drug Carrier for Intravesical Bladder Cancer Therapy. Eur J Pharm Sci. 2015 May 25;72:57-68.
  27. Chan E, Pasikanti KK, Hong Y, Ho P, Mahendran R, Lata RNM, Chiong E, Esuvaranathan K. Metabonomic profiling of bladder cancer. J Proteome Res. 2015 Feb 6;14(2):587-602.
  28. Chittezhath M, Dhillon MK, Lim JY, Laoui D, Shalova IN, Teo Y, Chen J, Kamaraj R, Raman L, Lum J,  Thamboo TP, Chiong E, Zolezzi F, Yang H,  Van Ginderachter JA, Poidinger M, Wong ASC, Biswas SK. Molecular profiling reveals a tumor promoting phenotype of monocytes and macrophages in human cancer progression. Immunity 2014 Nov 20;41(5):815-29. (Impact Factor 20.948)
  29. Wang R, Neoh KG, Kang ET, Tambyah PA, Chiong E. Antifouling Coating with Controllable and Sustained Silver Release for Long-term Inhibition of Infection and Encrustation in Urinary Catheters. J Biomed Mater Res B Appl Biomater. 2015 Apr;103(3):519-28
  30. Zhang Q, Neoh KG, Xu LQ, Lu SJ, Kang ET, Mahendran R, Chiong E. Functionalized Mesoporous Silica Nanoparticles with Mucoadhesive and Sustained Drug Release Properties for Potential Bladder Cancer Therapy. Langmuir 2014 Jun 3;30(21):6151-61.
  31. Williams S, Chiong E (Co-1st author), Lojanapiwat B, Umbas R, Akaza H. Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncology 2013 Nov;14(12):e524-34.
  32. Pasikanti KK, Esuvaranathan K, Hong Y, Ho P, Mahendran R, Lata RNM, Chiong E, Chan E. Urinary metabotyping of bladder cancer using two dimensional gas chromatography time-of-flight mass spectrometry. J Proteome Res. 2013 Sep 6;12(9):3865-73.
  33. Sim HG, Lim KHC, Tay MH, Chong KT, Chiong E. Guidelines on Management of Prostate Cancer. Annals Academy of Medicine, Singapore 2013 Apr;42(4):190-9.
  34. Li M, Neoh KG, Xu LQ, Wang R, Kang ET, Lau T, Olszyna D, Chiong E. Surface Modification of Silicone for Biomedical Applications Requiring Long Term Antibacterial, Antifouling and Haemocompatible Properties. Langmuir 2012 Nov 27;28(47):16408-22.
  35. Chiong E, Tay MH, Tan MH, Kumar S, Sim HG, Teh BT, Umbas R, Chau NM. Management of Kidney Cancer in Asia: Consensus Statement from the Asian Oncology Summit 2012. Lancet Oncology 2012 Nov;13(11):e482-91. (Impact Factor 25.117).
  36. Huang C, Neoh KG, XU L, Kang ET, Chiong E. Polymeric Nanoparticles with Encapsulated Superparamagnetic Iron Oxide and Conjugated Cisplatin for Potential Bladder Cancer Therapy. Biomacromolecules 2012 Aug; 13(8):2513-20.
  37. Wang R, Neoh KG, Shi Z, Kang ET, Tambyah PA, Chiong E. Inhibition of Escherichia coli and Proteus mirabilis Adhesion and Biofilm Formation on Medical Grade Silicone Surface. Biotechnol Bioeng. 2012 Feb;109(2):336-45
  38. Chiong E, Lee I, Dadbin A, Sabichi AL, Harris L, Urbauer D, McConkey D, Dickstein RJ, Cheng T, Grossman HB. Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells. Clin Cancer Res. 2011 May 1; 17(9):2863-73. 
  39. Chiong E, Kesavan A, Mahendran R, Chan YH, Sng JH, Lim YK, Kamaraj R, Tan TM, Esuvaranathan K.. NRAMP1 and hGPX1 Gene Polymorphism and Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer. Eur Urol. 2011 Mar;59(3):430-7.

Professional Memberships

Fellow, The Royal College of Surgeons In Ireland

Fellow, The Royal College of Surgeons of Edinburgh

Full Registered Member, General Medical Council, United Kingdom

Life Member, Singapore Urological Association

Fellow, Academy of Medicine, Singapore

International Member, American Urological Association

Member, American Society of Clinical Oncology

Member European Association of Urology

Member, Urological Association of Asia

Member, Robotic Surgery Society of Singapore

Member, Asia Pacific Society of Uro-Oncology

Member, Asian Urological Surgery Society (ARUS), Urological Association of Asia